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Background. Triglyceride-rich lipoproteins and their
remnants have emerged as major risk factors for
cardiovascular disease. New experimental appro-
aches are required that permit simultaneous inves-
tigation of the dynamics of chylomicrons (CM) and
apoB48 metabolism and of apoB100 in very low-
density lipoproteins (VLDL).
Methods. Mass spectrometric techniques were used
to determine the masses and tracer enrichments of
apoB48 in the CM, VLDL1 and VLDL2 density
intervals. An integrated non-steady-state multi-
compartmental model was constructed to describe
the metabolism of apoB48- and apoB100-containing
lipoproteins following a fat-rich meal, as well as
during prolonged fasting.
Results. The kinetic model described the metabolism
of apoB48 in CM, VLDL1 and VLDL2. It predicted a
low level of basal apoB48 secretion and, during fat
absorption, an increment in apoB48 release into
not only CM but also directly into VLDL1 and
VLDL2. ApoB48 particles with a long residence
time were present in VLDL, and in subjects with
high plasma triglycerides, these lipoproteins con-
tributed to apoB48 measured during fasting con-
ditions. Basal apoB48 secretion was about
50 mg day1, and the increment during absorption
was about 230 mg day1. The fractional catabolic
rates for apoB48 in VLDL1 and VLDL2 were sub-
stantially lower than for apoB48 in CM.
Discussion. This novel non-steady-state model inte-
grates the metabolic properties of both apoB100
and apoB48 and the kinetics of triglyceride. The
model is physiologically relevant and provides
insight not only into apoB48 release in the basal
and postabsorptive states but also into the contri-
bution of the intestine to VLDL pool size and
kinetics.
Keywords: apolipoprotein B48, kinetics, model, rem-
nants, stable isotope.
Introduction
Recent genetic and epidemiological studies have
provided evidence that plasma triglyceride-rich
lipoproteins (TRLs) play a causal role in
cardiovascular disease, and this has prompted
renewed interest in understanding better the meta-
bolism of these lipoproteins and their potential
contribution to atherogenesis [1–3]. There are two
major transporters of triglyceride in the circulation:
apolipoprotein (apo) B100-containing very low-
density lipoproteins (VLDL) which are released
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virtually constantly from the liver and apoB48-
containing chylomicrons which are secreted from
the intestine in a wave during dietary fat absorp-
tion. TRLs in the circulation are acted on first by
lipoprotein lipase to remove much of the core
triglyceride, and the resulting remnants are cleared
by cell-surface receptors [4], or in the case of VLDL
converted (in part) by further lipolysis to interme-
diate- and low-density lipoproteins. These lipid
metabolism pathways are quantitatively signifi-
cant; during fasting conditions in healthy individ-
uals, the liver releases about 20–70 g of VLDL
triglyceride per day associated with about 1 g of
apoB100, while the intestine absorbs and packages
in the order of 50–200 g of triglyceride daily
depending on the fat content of the diet [5, 6].
Conventionally, triglyceride-rich lipoproteins are
isolated by centrifugation and can be usefully
divided into three fractions: chylomicrons (CM)
with Sf (Svedberg flotation rate) >400, larger VLDL
(VLDL1) with Sf 60-400 and smaller VLDL (VLDL2)
with Sf 20-60. Newly secreted particles and their
partially lipolysed remnants (which are believed to
contribute particularly to the development of
atherosclerotic plaque [7]) can exist across the
entire size and density range. It follows that
development of a true picture of the physiology
of TRLs requires investigation of the non-steady-
state dynamics of chylomicron metabolism over-
layered on the (near) steady-state system of VLDL
kinetics. To date, this has been difficult to achieve
and it has been necessary to use analytical
approaches that are arguably over-simplistic
and/or employ nonphysiological nutritional regi-
mens [8–11]. For example, previous studies of
apoB48 metabolism have utilized a continuous
micro-meal feeding pattern to generate a quasi-
steady state or used a single metabolic compart-
ment to represent chylomicron kinetics following a
test meal [8, 9, 12–18]. The latter is closer to
normal physiology than the former but since the
model does not reflect the complexities of the
system, it limits the ability to apply the findings to
real-life nutritional settings.
In the present investigation, we used multiple
stable-isotope tracers, advanced mass spectromet-
ric techniques and developed a novel multicom-
partmental model to assess triglyceride, apoB48
and apoB100 kinetics throughout the lipolytic
cascade. The development of advanced mass spec-
trometric techniques was critical for this study as
they allowed the simultaneous measurement of
concentrations and turnover kinetics of several
apolipoproteins from a single digestion mixture
with superior sensitivity and specificity [19, 20].
This integrated approach enabled deeper insight
into the dynamics of triglyceride transport and its
potential consequences for atherogenesis and will
enable better understanding of the targets of new
therapeutic agents. The model included elements
that described successfully both the continuous
flux of VLDL from the liver and the non-steady-
state dynamics of chylomicron release in response
to a fat meal. It was constructed using data from
subjects with a range of fasting plasma triglyceride
concentrations (from 0.74 to 5.7 mmol L1) in
order to ensure its wide applicability.
Methods
Subjects
Two groups, each comprising four male volunteers,
were studied. They attended the metabolic clinic
after an overnight fast from 8:00 pm the previous
evening and were asked to refrain from strenuous
exercise and alcohol for 3 days prior to each
experimental phase. The protocol was approved
by the Helsinki University Ethics Committee, and
the volunteers gave written informed consent. The
first group of four subjects were selected to have
low, normal and elevated plasma triglyceride levels
in order to develop a model that could be applied to
the full range of triglyceride values. Each individ-
ual underwent two experimental protocols investi-
gating apoB48 and apoB100 kinetics, one in which
a fat-rich test meal was administered and the other
in the absence of a meal. The second group of four
subjects had normal plasma triglyceride levels and
were used to confirm the validity of the model (see
Appendix S1). No subjects with the apoE2/2 phe-
notype were included in the study.
Metabolic study protocol
To decipher the metabolism of postprandial lipid
metabolism, we performed stable-isotope studies
both in the postprandial state and in the fasting
state. Thus, each individual participated in two
kinetic studies. On the evening of the first visit
(fasting state), a blood sample was taken (Fig-
ure S1). At about 8.00 AM (study 0 h time-point),
deuterated leucine (5,5,5-D3 Euriso-Top, d3-leu-
cine) at a dose of 7 mg kg1 body weight and
deuterated glycerol (1,1,2,3,3-D5 Euriso-Top, d5-
glycerol) at an invariant dose of 500 mg (Isotec,
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Miamisburg, OH) were injected as a bolus. The
blood sampling schedule was immediately before
tracer injection and then at 2, 4, 6, 8, 10, 12, 15,
20, 30, and 45 min and 1, 2, 3, 4, 6, 8, 10 and 24 h
for the measurement of d3-leucine tracer concen-
trations in plasma. Samples taken before the
injection of tracers and at 30, 45, 60, 75, 90, 120
and 150 min and 3, 4, 5, 6, 8, 10 and 24 h after
were used for the measurement of d3-leucine
enrichment in apoB48 and apoB100 and d5-
glycerol enrichment in triglyceride in lipoprotein
fractions. For the second visit (postprandial state),
the study protocol was identical except that a
mixed meal (68.5 g fat, 63 g carbohydrates and
40 g protein, total energy content 1032 kcal) was
served 2 h after the infusions begin and consumed
within 10 min.
Lipoprotein preparation
Chylomicrons (CM; Sf > 400), VLDL1 (Sf 60-400)
and VLDL2 (Sf 20-60) were isolated by preparative
centrifugation as previously described [21]. Plasma
samples were overlayered with a gradient of salt
solutions of decreasing density and centrifugation
performed in three steps. Lipoprotein fractions
were harvested from the top of the centrifuge tube
and stored at 80 °C prior to processing.
Quantification of apoB48 in plasma and lipoprotein fractions
Stable-isotope-labelled apoB48-peptides (H-LSQ-
LQTYMI-OH and H-LSQLQTYMet(O)I-OH) were
purchased from JPT peptide Technologies (GmbH,
Berlin, Germany). The stable isotopes 13C (x6) and
15N (x1) were incorporated into the isoleucine
carboxyl terminal resulting in a mass shift of
7 Da. Purity for each peptide was >95%. The
stable-isotope-labelled peptides were used as inter-
nal standards (ISTDs) for quantification of apoB48.
The peptides were dissolved and diluted in
50 mmol L1 ammonium bicarbonate to an ISTD
master mix at concentrations of 0.025 pmol lL1
for apoB48 and apoB48-MetOx, respectively. Ini-
tially, calibration curves were prepared, in which
the linearity of the mass spectrometric determina-
tion of the peptides was verified with the ISTD
peptides spiked into representative pooled plasma
samples. A total of ten plasma digests (20 lL) were
prepared as described below with an equimolar
mixture of the two apoB48-peptides with varying
concentrations ranging from 0.025 to 1.250 pmol.
This corresponds to a concentration in the plasma
of 1.25 to 50 fmol lL1. Mass spectrometric
analyses and evaluation were performed as
described below. The mass spectrometry response
was found to be linear within this concentration
range for both peptides.
Tryptic digestion of plasma, VLDL1, VLDL2 and chylomicron fractions
Plasma samples and fractions were thawed at room
temperature and vortexed for 10 min. Twenty-one
microlitre of plasma was mixed with 189 lL
100 mmol L1 TEAB (triethylammoinium bicar-
bonate), 147 lL 5% sodium deoxycholate and
44 lL of 50 mmol L1 DTT (DL-dithiothreitol,
Sigma–Aldrich, Saint Louis, MO, USA). The sam-
ples were reduced for 20 min at 60 °C and then
alkylated with 20 lL 200 mmol L1 MMTS (S-
Methyl methanethiosulfonate, Sigma–Aldrich) for
20 min at room temperature. The reaction mixture
was then diluted in 300 lL 100 mmol L1 TEAB,
5 lL apoB48-peptide internal standard
(0.125 pmol) was added, and the mixture was
digested overnight with 70 lL (0.2 mg mL1) tryp-
sin (Pierce) at 37 °C. A second aliquot of trypsin
70 lL (0.2 mg mL1) was added, and digestion was
continued for 3 h at 37 °C. Twenty-one microlitre
of VLDL fractions was diluted five times in
100 mmol L1 TEAB, and 60 lL of the chylomicron
fraction was diluted in 140 mmol L1 TEAB
(40 lL). Seventy microlitre 5% sodium deoxy-
cholate and 21 lL 50 mmol L1 DTT were added,
and samples were reduced for 20 min at 60 °C and
then alkylated with 10.5 lL 200 mmol L1 MMTS
for 20 min at room temperature. The reaction
mixture was then diluted in 147 lL 100 mmol L1
TEAB, 5 lL apoB48-peptide internal standard
(0.125 pmol) was added, and the mixture was
digested overnight with 2 lL (0.1 mg mL1) trypsin
at 37 °C. A second aliquot of trypsin 2 lL
(0.1 mg mL1) was added, and digestion was con-
tinued for 3 h at 37 °C. The trypsin was inactivated
by heating the samples to 90 °C for 10 min before
immuno-enrichment.
Immuno-enrichment of apoB48
Since apoB48 is a low-abundance protein, we
utilized antipeptide antibodies to enrich apoB48
from digested samples, namely the stable-isotope-
labelled standards and capture by antipeptide
antibody approach [22]. Antibodies for apoB48
were coupled to magnetic beads (Dynabeads
Protein A, Life Technologies, Oslo, Norway) accord-
ing to manufacturer’s instructions [20]. After
coupling, the bead-antibody complex was blocked
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in Roti block (Carl Roth GmbH, Karlsruhe, Ger-
many), for 30 min at room temperature. Antibody
(10 lg) was used to couple 42 lL of protein A
beads. Coupled beads were resuspended in the
same volume 0.1% PBS-Tween-20 solution. For
enrichment of apoB48 peptide in plasma, 100 lL
0.2% PBS-Tween-20 with 10X protease inhibitor
(cOmplete Tablets, Mini, EDTA-free, Roche Diag-
nostics GmbH, Mannheim, Germany), and anti-
body-coupled beads (42 lL beads coupled to 10 lg
antibody) were added to 880 lL digested plasma.
For enrichment of apoB48 peptide in VLDL and
chylomicron fractions, 37 lL 0.2% PBS-Tween-20
with 10X protease inhibitor, (cOmplete Tablets,
Mini, EDTA-free, Roche Diagnostics GmbH, Man-
nheim, Germany) and antibody-coupled beads
(21 lL beads coupled to 5 lg antibody) were added
to 330 lL digested fraction. The mixture was
incubated at 4 °C overnight with rotation. The next
day, beads were washed twice with 0.6 mL 0.02%
PBS-Tween-20 solution, once with 0.6 mL PBS and
twice with 0.6 mL 100 mmol L1 TEAB. Peptides
were eluted with 50 lL elution buffer (water solu-
tion containing 1% formic acid) at 37 °C for 15 min
with gentle rocking. The eluted samples were
desalted on a SOLAl HRP 96-well plate (Thermo
Scientific) using a positive pressure manifold (Bio-
tage) and spun in a Speed-Vac with low heat to
dryness. For LC/MS analysis, the samples were
resuspended in 15 lL solution containing 3% ace-
tonitrile and 3% formic acid.
Determination of leucine enrichment in apoB100 and of glycerol
enrichment in triglycerides
ApoB100 isolated from VLDL1 and VLDL2 was
hydrolysed, derivatized and subjected to gas
chromatography mass spectrometry (GC/MS) to
measure tracer leucine enrichment [5, 23]. Triglyc-
erides were isolated from lipoproteins and the
tracer glycerol enrichment determined as previ-
ously described [5].
Biochemical analyses
Fasting plasma glucose, triglycerides, HDL choles-
terol, LDL cholesterol and plasma liver enzymes
were determined by automated enzymatic methods
using the Konelab 60i analyser (Thermo Fisher
Scientific, Finland). Plasma levels of apoCIII were
measured immunoturbidometrically (Kamiya Bio-
medical Company, Seattle, WA, USA). Fasting and
postprandial apolipoprotein (apo) B48 and apo-
B100 levels in total plasma were measured by
ELISA (Shibayagi, Shibukawa, Japan). Plasma
non-esterified fatty acids (NEFA) were analysed
with an automated enzymatic colorimetric method
(Wako Chemicals, Neuss, Germany). Postheparin
LPL and HL activities were measured as described
[24].
Results
Characteristics of the four subjects used to develop
the model in terms of age, sex, body weight and
plasma lipid indices are given in Table 1. Body
weights and BMI were similar, while plasma
triglyceride levels (by design) varied from low
normal (0.74 mmol L1) to high (5.7 mmol L1).
Each person underwent two studies, that is with
and without administration of a fat-rich test meal
and the time between the two experimental phases
varied from 2 to 8 months. The values in Table 1
were obtained during the study phase when the
meal was given.
Data fromwhich todevelop themulticompartmental
modelwere extensive, anda typical set (for subject 3)
isprovided inFig. 1.During thestudyphase,whena
test meal was given, it comprised, in addition to
plasma free leucine enrichment (panel A), (i) the
change in concentration of triglyceride in plasma,
CM, VLDL1 and VLDL2 (panels J, L, M, N); (ii) the
change in concentration of apoB48 in plasma, CM,
VLDL1 andVLDL2 (panels K, Q, R, S); (iii) the change
in concentration of apoB100 in VLDL1 and VLDL2
(panels O, P); (iv) the enrichment of deuterated
glycerol in triglyceride in VLDL1 and VLDL2 (panels
H, I); (v) the enrichment of deuterated leucine in
apoB48 inplasma,CM,VLDL1andVLDL2 (panelsB,
C, D, E); and (vi) the enrichment of deuterated
leucine in apoB100 in VLDL1 and VLDL2 (panels F,
G). The model was fitted to all components (pools
and enrichments) simultaneously, and as seen in
Fig. 1, there was good agreement between the
observed data (circles) and the simulated curves
(lines).
Change in plasma apoB48 concentrations and
apoB48 enrichment across the experimental obser-
vation period for the study phase when the sub-
jects were not given a test meal are given in Fig. 2.
Note the observations start at time 0 h and the
simulated prior day was incorporated as described
below. These data were also submitted to modelling
in a separate fitting process to generate production
and clearance rates and change in concentration
for apoB48 in fasting conditions.
Model of human apoB kinetics / E. Bj€ornson et al.
4 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
Overall model structure
The final multicompartmental model, which
accounted adequately for the d3-leucine and
d5-glycerol tracer enrichments and the change
in concentration of apoB48 and triglyceride in
the CM fraction, and apoB48, apoB100 and
triglyceride in the VLDL1 and VLDL2 fractions,
is shown in Fig. 3. As is clear from the data in
Fig. 1, it is a non-steady-state model in which
concentrations change with time in not only the
CM fractions but also in VLDL1 and VLDL2. A
complex compartmental structure was required
to fit the observations as described for each
section of the model below. It should be noted
that in a non-steady-state analysis, the tracer/
tracee ratio (Fig. 1) used as a measure of enrich-
ment in the fitting procedure is a function of both
change in tracer (deuterated leucine or glycerol)
and tracee (triglyceride, apoB48 or apoB100
mass). Hence, the enrichment and mass data
must both be used simultaneously to generate
fitted curves.
Modelling of plasma leucine and glycerol tracers
Plasma leucine (compartment 27–29, Fig. 3) was
modelled as a three compartment subsystem as
described previously [5]. Compartment 27 repre-
sents the compartment where tracer was injected.
Compartments 28 and 29 represent tissue pools
and interstitial fluid, respectively, in rapid
equilibrium with plasma. Plasma d3-leucine is
taken up by the intestine (comp 30) and liver
(comp 32) and after a delay (comps 30 + 31; comps
32 + 33), while the apoB peptide chain is synthe-
sized appears in secreted apoB48 (comps 13, 14,
16–19) and apoB100 (comps 1 and 4). Plasma
glycerol was modelled as a two compartment
subsystem. Compartment 38 represents plasma
d5-glycerol, and compartment 39 represents other
rapidly exchanging bodily pools of glycerol. The d5-
glycerol moves via delay compartments 40/41 into
the liver where it is incorporated into newly syn-
thesized VLDL1- and VLDL2-TG. It is assumed that
d5-glycerol does not become incorporated into the
triglyceride of intestinally derived lipoproteins
since enterocytes possess minimal glycerol kinase
activity [25, 26].
Modelling of apoB100 and TG in VLDL1 and VLDL2
Kinetics of apoB100 were described using three
compartments in the VLDL1 fraction (comps 1, 2, 3)
and three in the VLDL2 fraction (comps 4, 5, 6) as
previously published [5]. This allowed for a ‘delip-
idation chain’ within each lipoprotein fraction;
compartment 1 (see Fig. 3) transferred material to
compartments 2 and 3 as lipolysis progressed (i.e.
as triglyceride was removed from the particle).
Compartments 2 and 3 permitted both rapid (comp
2) and slow removal (comp 3) from the VLDL1
fraction. A similar structure was employed in
VLDL2 with compartments 4, 5 and 6.
Table 1 Characteristics of the four subjects. Subjects had similar anthropometric measurements; BMI, body weight and waist
but showed variation in lipid-related variables; plasma triglycerides, apoC-III, apoB, LDL-C and HDL-C. All variables except
LPL/HL activity are measured during the postprandial test day.
Subject 1 Subject 2 Subject 3 Subject 4
Age (y) 59 43 64 56
Body weight (kg) 92.5 89.1 93.1 98.5
BMI (kg m2) 30.1 29.8 31.8 30.6
Waist (cm) 104 98 113 100
Triglycerides (mmol L1) 0.74 1.1 2.1 5.7
ApoC-III (mg dL1) 9.9 11.7 15.6 22.8
ApoB (mg dL1) 69 96 115 125
Total chol (mmol L1) 4.7 5.1 5.4 6.9
LDL chol (mmol L1) 2.7 3.4 3.1 3.8
HDL chol (mmol L1) 1.7 1.3 1.3 0.85
FFA (lmol L1) 450 372 351 260
LPL activity (mU mL1) 199 130 129 114
HL activity (mU mL1) 232 254 178 210
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Triglyceride concentrations and enrichments in
VLDL1 and VLDL2 were modelled as before using
a compartmental structure that mirrored that of
apoB100 (comps 7, 8 and 9 and comps 10, 11 and
12) [5]. Rate constants describing the fluxes to and
from compartments 1–6 and 7–12 were allowed to
vary freely, but the VLDL1/VLDL2 apoB100 (comps
1-6) and VLDL1/VLDL2-TG subsystems (comps 7–
12 in Fig. 1) were linked by setting the rate
constants equal to each other [e.g. k(0,5) = k
(0,11)]. The production rates of apoB100 and
VLDL-TG were also linked to each other. In VLDL1,
the TG/apoB100 ratio in compartments 1 and 7
were set equal as were the TG/apoB100 ratio
in compartments 2, 3, 8 and 9. Likewise in
VLDL2, the TG/apoB100 ratio was set equal in
Fig. 1 Model fits to experimental data for subject 3 – a representative subject. All tracer-to-tracee ratio data (for leucine and
glycerol enrichment) in the different fractions are depicted in sub figures a–i, followed by concentration data depicted in
subfigures j–s. For model fits to all subjects, see Appendix S1. Plasma leucine enr (enrichment) is plotted in semilogarithmic
scale. APE, atom percent excess; TTR, tracer-to-tracee ratio.
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compartments 4 and 10, and again, the ratio was
equal in compartments 5, 6, 11 and 12. The
resulting four TG/apoB100 ratios were variables
in the model which adjusted according to the rate
of delipidation (see Table S1).
Modelling of apoB48 in CM, VLDL1 and VLDL2
Concentrations of apoB48 and triglyceride in
apoB48-containing particles and their tracer
enrichments were modelled using three compart-
ments in the CM fraction (13–15 and 20–22) and
two compartments in VLDL1 (16,17 and 23,34) and
VLDL2 (18,19 and 25,26). The number of subcom-
partments was chosen as a compromise between
being able to fit the experimental data for a broad
range of subjects (normo- to hypertriglyceridemic)
and having a parsimonious model structure. The
CM apoB48 subsystem had three compartments to
allow (as in VLDL1/2) for a delipidation chain since
a newly secreted chylomicron particle likely con-
tains more TG per apoB48 than the average
circulating particle in the CM fraction. Accordingly,
compartment 13 was allowed to have a higher TG/
apoB48 ratio while compartments 14 and 15 were
set to have equal, lower TG/apoB48 ratios. Thus,
in this model, it is envisaged that newly secreted
chylomicrons enter compartment 13 and are delip-
idated rapidly within the CM fraction to two species
with faster (comp 14) and slower (comp 15) ongoing
delipidation rates. Further lipolysis leads to the
formation of apoB48-containing remnants first
within the VLDL1 fraction (comps 16, 17) and then
in the VLDL2 fraction (comps 18, 19). The struc-
ture of the apoB48 subsystem in the VLDL1 and
VLDL2 fractions (Fig. 1) was a simplified version of
the apoB100 model with two compartments in each
density interval (comps 16 and 17 represent
apoB48 in the VLDL1 fraction; comps 18 and 19
represent apoB48 in VLDL2) being sufficient to
describe the experimental data; there was no
requirement for a delipidation chain structure.
Compartments 16 and 18 have relatively rapid
fractional transfer/clearance rates; compartments
17 and 19 are slower. Inclusion of the latter
compartments allow slow decaying species as seen
in the tracer curves especially in subjects with
higher triglyceride levels. While the TG/apoB48
ratio in the CM fraction is experimentally verifiable,
and hence, an adjustable variable in the fitting
process the triglyceride associated with apoB48 in
the VLDL1 and VLDL2 ranges is not measured but
is connected to the apoB48 model via coupling of
rate constants and production rates (as for the
apoB100 model). Its kinetics can be simulated as
in compartments 20 to 26 and will be a component
of the measured triglyceride in VLDL1 and VLDL2.
Postprandial triglyceride secretion
It is established experimentally that intestinal
triglyceride absorption is near complete and does
not vary substantially between subjects [27–29].
The consequence of this observation for modelling
purposes is that total TG secretion in apoB48-
containing particles should largely be determined
by the amount of fat in the test meal. Therefore, we
assumed a 95% uptake of the dietary fat in the test
meal in all subjects. The timing of the apoB48-TG
secretion was, however, free to vary between indi-
viduals, and the total apoB48 secretion was not
subject to any direct constraints.
Features of apoB48 and chylomicron metabolism in the integrated
model
Postprandial apoB48 secretion
In the model when dietary triglyceride is absorbed,
it appears first in compartment 48 which repre-
sents lipid in the intestinal tract. To account for the
subsequent appearance of apoB48 in the blood-
stream, two possible modelling structures were
tested, one in which all apoB48-associated lipopro-
tein secretion in response to the test meal occurred
in the CM fraction and could only appear in the
VLDL1 and VLDL2 density ranges through lipolysis,
and a second in which direct postprandial secre-
tion of apoB48 lipoproteins into the VLDL1 and
VLDL2 fraction was allowed. The first option did
not fit the experimental data well – observed data
points fell consistently above the simulated rise
curve in both VLDL fractions. When direct secre-
tion was permitted (i.e. transfer from comp 48 to
comps 52 and 53 as well as 49 and 51), there was a
good fit and so this arrangement was incorporated
into the final model (Figs. 3, S2). With this com-
partmental structure, it was found that in response
to the test meal while >95% of absorbed TG
appeared in the CM fraction (Fig. 1c,l), a substan-
tial proportion of total apoB48 secretion occurred
in the VLDL1 and VLDL2 fractions (Fig. 1d,e).
Basal apoB48 secretion
To assess the level of basal apoB48 secretion (i.e.
apoB48 secretion which persists even during pro-
longed fasting) and to distinguish this from diet-
induced apoB48 secretion, we tested the subjects
twice using identical tracer protocols but on one
occasion no meal was given. The results of the
fasting experiment in terms of total plasma apoB48
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concentration and tracer enrichment are presented
in Fig. 2. There were measurable concentrations of
plasma apoB48 in all four subjects during the
prolonged fast, and these levels decreased with
time in subjects 3 and 4 where apoB48 was initially
high. Subject 1 had low levels throughout. There
was clear synthesis and secretion of apoB48 in the
fasting state as evidenced by the d3-leucine enrich-
ment curves. For the four subjects, the mean basal
secretion rate during the fasting experiment was
74  29 mg day1 (range 41–108 mg day1) which
was not significantly different (P-value = 0.42, two-
tailed t-test) from the estimated rate during the
postprandial experiment (53  30 mg day1,
range 27–101 mg day1).
Modelling the previous day
It is clear from the data depicted in Figs 1 and 2
that measurable levels of plasma and VLDL1 and
VLDL2 apoB48 were present even in subjects who
had fasted overnight. These particles could result
from continuous significant levels of basal secre-
tion and/or the presence of slowly metabolized
apoB48-containing remnants of chylomicron meta-
bolism that persisted for many hours after absorp-
tion was complete. The findings of the ‘fasting’
experiment indicated that both of these phenom-
ena occur and it was necessary to accommodate
this in the model. Accordingly, a ‘previous day’ was
introduced (Figs 2 and 4, shaded area in the
panels) to allow for the existence and persistence
of these apoB48 particles. In the compartmental
model, the particles were assigned the same kinetic
behaviour (rate constants) as those measured
directly in response to the test meal. Since the
exact dietary fat intake was not known, a typical
intake was assumed with three main meals (break-
fast, lunch, dinner) and two snacks (afternoon and
evening). These were modelled with the assump-
tion of a total fat intake of 100 g for the day (for
details, see Appendix S1).
Fluxes and concentrations of apoB48 vs apoB100
In this limited group of subjects, mean basal
apoB48 production during the postprandial test
day was 53 mg day1 which was small compared
to the mean apoB100 production of 1157 mg day1
(range 739–1320 mg day1; Table 2). Mean
apoB48 production rate in response to the test
meal was 230 mg day1 (range 85–388 mg day1).
For a typical day assuming a dietary fat intake of
100 g, this would correspond to around 300 mg of
apoB48 secreted per day. This production rate is
predicted by the model to vary substantially
between subjects, and it will be a function of
dietary fat intake. Allowing for the difference in
molecular weight between the two apoB proteins,
apoB48 particles accounted for about 30% of the
total number of secreted TRL particles. It was
Fig. 2 Model fits to plasma apoB48 and plasma apoB48 enrichment during fasting conditions for the four subjects. Since
data were not available in the CM, VLDL1 and VLDL2 fraction, the model was fitted to only the total plasma measurements.
Total plasma apoB48 concentration is shown in the top row (a–d) for each subject, and total plasma apoB48 enrichment is
shown in the bottom row (e–h) for each subject. Modelling of the previous day is indicated with grey background.
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noteworthy that the FCR of apoB48 in VLDL1 and
VLDL2 density ranges was less than that in the CM
fraction and also less than the FCR for apoB100
(Table 2). These observations lend weight to the
concept that apoB48 in the VLDL fractions is
present on slowly metabolized remnants.
Dynamics of TG transport in apoB48- and apoB100-containing
lipoproteins
The triglyceride content of apoB48-containing par-
ticles in the VLDL fraction was calculated from the
apoB48 protein flux and the estimated TG/apoB48
ratio in particles in the VLDL density range. It was
predicted to be small compared to the triglyceride
content of apoB100-containing VLDL counter-
parts, but not negligible. During peak postpran-
dial conditions, roughly 10–20% of the TG in the
VLDL-fraction was predicted to be in apoB48
particles. However, during fasting, this dropped
to around 5% or less. The largest discrepancy
between flux and concentration is seen for TG in
the CM fraction (Fig. 4). Although the TG flux in
the CM fraction is around an order of magnitude
higher than, for example, the TG in the VLDL1
fraction, the concentration ratio is around 1:1 at
peak postprandial conditions. Basal TG secretion
in apoB48-containing particles was predicted to
be low at about 1.1 g day1 on average (range 0.6–
1.5 g day1).
Fig. 3 The final integrated model structure. Compartments 1-6 represents apoB100 in VLDL1 and VLDL2 fraction;
compartments 7–12 represents apoB100-TG in VLDL1 and VLDL2 fraction; compartments 13–19 represents apoB48 in CM,
VLDL1 and VLDL2 fraction; compartments 20–26 represents apoB48-TG in CM, VLDL1 and VLDL2 fraction. Plasma leucine
and plasma glycerol are represented by compartments 27–29 and 38–39, respectively. Blue arrows indicate where
postprandial fluxes of apoB48/apoB48-TG enter the model. The above structure represents a simplified schematic version
of the full model (see Figure S2).
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Validation of model
To validate the model, we performed kinetic studies
in four additional overweight or obese subjects.
These subjects underwent the same kinetic study
protocol. This second cohort had an average
plasma triglycerides of 1.3 mmol L1 (range 0.9–
1.7 mmol L1) and was selected to be more repre-
sentative of a normal population in terms of plasma
triglycerides than the first cohort which had a
Fig. 4 (a) Fluxes of apoB48 in CM, VLDL1 and VLDL2 and fluxes of apoB100 in VLDL1 and VLDL2; (b) Concentrations of
apoB48 in CM, VLDL1 and VLDL2 and concentration of apoB100 in VLDL1 and VLDL2; (c) ApoB48-TG flux in CM, VLDL1 and
VLDL2 and apoB100-TG flux in VLDL1 and VLDL2; (d) ApoB48-TG concentration in CM, VLDL1 and VLDL2. Solid lines
indicate model predictions and coloured circles indicate experimental data. Modelling of the previous day is indicated with
grey background. The concentration and flux (in terms of mass) of apoB100 is higher than that of apoB48 in the VLDL1/2
fractions. Total apoB48 flux into the CM fraction is higher than the basal apoB48 flux, and postprandial apoB48 flux also
constitutes a significant portion of the total postprandial apoB48 flux. The total triglyceride flux into the CM fraction is the
biggest source of triglyceride flux. However, VLDL1-TG concentration is higher than CM-TG concentration because of the high
CM-TG FCR.
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wider range of plasma triglycerides. Baseline char-
acteristics of the four additional subjects are
shown in Table S2. The kinetic parameters for the
first cohort and the second cohort are compared in
Figure S5. The results indicate general agreement
between the first and second cohort results and
indicate future applicability of the model to a
‘normal population’ setting.
Table 2 Individual and mean (SD) kinetic parameters for the four subjects. Between-subject variation is mostly evident in
several apoB48- and apoB100-related FCR values. Between-subject variability exists in basal and total apoB48 production
rates. All subjects have low basal apoB48-TG rates. Mean apoB100 production rate in VLDL1 and VLDL2 is in line with
previously published results [5]. FCR, fractional catabolic rate, FDC, fractional direct catabolism, FTR, fractional transfer
rate, prod, production, dir, direct, tot, total. Postprandial prod refers to the incremental secretion in response to the test meal
in addition to the basal secretion. For explanation of calculations of FCR, FDC and FTR, see Appendix S1.
Subject 1 Subject 2 Subject 3 Subject 4 Mean  SD
Mean  SD
second cohort
ApoB48 kinetic parameters
ApoB48 tot prod (mg day1) 248 416 142 327 283  100 332  99
ApoB48 basal prod (mg day1) 27.8 27.3 57.4 101 53.4  30 61.8  4.3
ApoB48 postprandial prod (mg day1) 220 388 85 226 230  110 270  96
ApoB48 tot FCR (pools day1) 17.5 27.5 3.0 2.0 12.5  11 6.3  2.2
ApoB48 CM FCR (pools day1) 49.9 26.5 4.5 5.1 21.3  19 24.6  21
ApoB48 VLDL1 FCR (pools day1) 1.5 5.0 1.7 1.5 2.4  1.5 12.3  8.8
ApoB48 VLDL2 FCR (pools day1) 3.8 19 3.0 0.9 6.7  7.2 10.7  2.4
ApoB48-TG kinetic parameters
TG apoB48 tot prod (g day1) 67.8 67.1 68 67.7 67.6  0.3 54.8  0.38
TG apoB48 basal prod (g day1) 1.3 0.6 1.5 1.2 1.1  0.3 0.78  0.37
TG apoB48 postprandial prod (g day1) 66.5 66.5 66.5 66.5 66.5  0 53.2  0.37
TG apoB48 CM FCR (pools day1) 238 44 55 23.5 83.4  90 44  15
TG apoB48 VLDL1 FCR (pools day1) 3.4 23.2 2.5 3.1 8.1  8.8 4.6  3.6
TG apoB48 VLDL2 FCR (pools day1) 12.9 23.1 4 1.3 10.3  8.5 5.1  4.0
ApoB100 kinetic parameters
ApoB100 VLDL1 FCR (pools day1) 51.9 18.7 10.4 1.9 20.7  19 15.3  9.5
ApoB100 VLDL1 FDC (pools day1) 33.1 13.4 9.2 0.6 14.1  12 4.2  3.5
ApoB100 VLDL1 FTR (pools day1) 18.8 5.3 1.1 1.4 6.6  7.2 11.2  7
ApoB100 VLDL1 prod (mg day1) 1080 960 987 559 890  200 710  130
ApoB100 VLDL2 FCR (pools day1) 6.3 3.1 2.8 1 3.3  1.9 3.8  1.4
ApoB100 VLDL2 prod (mg day1) 607 633 418 578 559  84 765  150
ApoB100 VLDL2 dir prod (mg day1) 216 360 312 180 267  72 266  120
ApoB100 VLDL tot prod (mg day1) 1296 1320 1272 739.2 1157  240 976  73
ApoB100-TG kinetic parameters
TG apoB100 VLDL1 FCR (pools day1) 58.6 20.4 12.1 2.3 23.4  21 28.3  20
TG apoB100 VLDL1 FDC (pools day1) 43.1 15.3 11.6 1.5 17.9  15 19.4  15
TG apoB100 VLDL1 FTR (pools day1) 15.5 5.1 0.6 0.8 5.5  6.1 9.0  5.7
TG apoB100 VLDL1 prod (g day1) 31.3 27.8 29.1 14.7 25.7  6.5 24.3  11
TG apoB100 VLDL2 FCR (pools day1) 33.8 17.6 4.6 2.8 14.7  12 15.5  10
TG apoB100 VLDL2 prod (g day1) 12.9 16.2 5.3 7.5 10.5  4.3 11.9  2.3
TG apoB100 VLDL2 dir prod (g day1) 4.6 9.2 4 2.3 5.0  2.6 4.2  1.9
TG apoB100 VLDL tot prod (g day1) 35.9 37 33 17.1 31  8 28.4  11
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Discussion
Renewed interest in the atherogenic potential of
triglyceride-rich lipoproteins requires deeper insight
into how these routes of mass lipid transport are
controlled and where dysregulation can lead to
increased risk of CHD. Further, recent identifica-
tion of possible novel therapeutic targets such as
apoC3 and ANGPTL3 mandates further exploration
of how these and other agencies impact on the
complex, integrated pathways of VLDL and chy-
lomicron metabolism [30–32]. The present study
offers a new approach to determining the kinetics
of triglyceride transport in a setting that more
closely reflects normal physiology where across the
day there are waves of fat absorption. Arguably
until we have good models of chylomicron and
apoB48 metabolism, we have limited ability to
determine in detail the influence of diet (especially
dietary fat) and drugs on this lipoprotein pathway
in man.
Key findings from the present study are (i) apoB48
is secreted continuously from the intestine in a
basal turnover state at a rate that is less than that
reported in previous studies [8, 9, 12–17], (ii)
apoB48 is released in lipoprotein particles across
a wide density and size range – from chylomicrons
to VLDL1 and VLDL2, (iii) apoB48 lipoproteins in
the VLDL density range can be long-lived and
persist even after a prolonged (overnight) fast, and
(iv) a significant proportion of VLDL mass com-
prises apoB48 particles which have metabolic
characteristics that appear to differ from those of
apoB100-containing VLDL. The contribution of
this range of apoB48-containing particles, espe-
cially remnants, to the formation of atherosclerotic
lesions is yet to be fully elucidated. What is clear is
that examination of VLDL kinetics in the fasted
state as undertaken by ourselves and others is a
convenient approximation to reality that has
yielded a great deal of useful information [5, 33–
36]. However, the true physiological picture is that
of a dynamic system in which VLDL and chylomi-
cron transport are interlinked and both undergo
substantial variation in concentration and kinetic
behaviour across the day.
Developing an understanding of the metabolism of
apoB48 has been challenging due to the low
abundance of this protein in the circulation and
the requirement to separate it effectively from the
large amount of apoB100 present in TRLs. Use of
techniques such as gel electrophoresis to isolate
the two apoB proteins usually limits investigation
to the whole TRL fraction since there is, especially
in normal subjects, insufficient material to exam-
ine CM and VLDL particles separately. There is
also the need to introduce steady-state-like condi-
tions if experimental protocols such as primed
constant infusion of tracers are used (in distinc-
tion to bolus injections). The micro-meal feeding
pattern employed by a number of investigators [8,
10, 11, 18] leads to a relatively constant level of
TRL apoB48 across the day and rates of overall
apoB48 secretion are reported to be about
73 mg day1 in normal [37] to 644 mg day1 in
diabetics [10] with apoB48 FCRs of 4.3 and
3.7 pools day1, respectively. However, this
approach cannot distinguish between basal secre-
tion of apoB48-containing particles during the
postabsorptive state and the increment which
accompanies fat absorption and this limits inter-
pretation of the findings, although effects of obe-
sity [12] and antidiabetic drugs [10] have been
documented. In the initial four subjects examined
in the present study, apoB48 total FCR ranged
from 27.5 to 2 pools day1, dropping off markedly
as plasma triglyceride rose from low normal to
high. Total apoB48 production integrated over
24 h was 142 to 416 mg day1.
Seeking to understand better the impact of a fat
load on apoB48 metabolism, Wong et al. [12, 13]
employed (as we did) a test meal and followed the
increase in apoB48 mass and tracer enrichment
across the day: again, the whole TRL fraction was
analysed. They reported incremental rates of
apoB48 secretion of about 40–100 mg over 10 h
in response to the fat meal and an invariant FCR
for TRL apoB48 of about 11–16 pools day1. These
values can be compared to the 230 mg day1
(range 85–388 mg day1) increment in our study
and a similar average total FCR of 18 pools day1.
To account for the observed fasting concentration
of apoB48, they invoked basal secretion rates of the
order of 340 mg day1 in normal subjects which is
very high and implies that the intestine releases
several times more apoB48 particles when fat is
absent than when it is present; further, if the
particles released were of the size of VLDL or
chylomicrons, this would imply a basal triglyceride
secretion of hundreds of grams which is clearly not
a physiologically relevant proposition.
It has been a longstanding observation that signif-
icant levels of apoB48 can be detected even after an
overnight fast with ‘fasting’ apoB48 reported to be
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in the order of 5 mg L1 [38], which would corre-
spond to around 5% of all apoB in the VLDL
fraction, but with a range from <1 mg L1 up to
60 mg L1 [39–45]. The source and nature of this
apoB has been the subject of speculation; is it, as
reported in the study of Wong et al. [12] the result
of basal secretion into the CM size range or into
smaller lipoprotein fractions, or is the protein
present on chylomicron remnant lipoproteins that
have a long residence time? A key observation,
which we believe helps resolve this, was the finding
in the present investigation that during prolonged
fasting where baseline (time 0 h) apoB48 levels
were high, the concentration decayed with time
and did not approach zero for a further approxi-
mately 12 h. Thus, we had to build into the final
model the existence of apoB48 particles that had
been generated during the previous 24 h (the
simulated ‘previous day’). Inclusion of this feature
accounted for a significant quantity of ‘fasting’
apoB48, and the basal rates that we observed in
this admittedly limited number of subjects were
low and hence physiologically plausible.
Recent studies have documented the presence of
cytoplasmic lipid droplets in enterocytes before,
during and after dietary fat absorption and so care
must be taken in interpreting the impetus to
continued apoB48 secretion in the ‘fasting’ state
[46]. These droplets appear to act as a ‘buffer’ to
allow rapid fat uptake from the diet and controlled
release of lipoprotein particles. Thus, the apoB48
synthesis and secretion we observed in subjects
12 h after food intake could have been associated
with lipid-poor particles [47] or triglyceride trans-
porting particles assembled using lipid stored in
cytoplasmic droplets [48]. Further metabolic inves-
tigations will be required to distinguish between
these possibilities.
As mentioned above, many investigators have lim-
ited studyof apoB48kinetics to the total TRLdensity
range (d < 1.006 kg L1) interval due to the need to
isolate sufficient quantities of the protein for anal-
ysis. Using advanced mass spectrometric analysis,
we were able to quantify the mass and tracer
enrichments of apoB48 in the VLDL1 and VLDL2
fractions. This was an important step forward since
it became clear that the kinetic behaviour of apoB48
differed in VLDL compared to CM. It was observed
thatwhile the largest source of postprandial apoB48
secretion occurred in the CM fraction, most (around
80% in average for the four subjects) of the apoB48
carrying lipoproteins during a typical day existed in
the VLDL density range (Fig. 4). In addition, we
observed direct secretion of apoB48 particles into
both VLDL1 and VLDL2 and clearance was also
directly from these density intervals. It follows that
in many subjects, the intestine through the elabo-
ration and secretion of apoB48 particles is a previ-
ously unrecognized contributor to VLDL
metabolism in man. About 91 mg day1 (range 26–
206 mg day1) of apoB48 was secreted directly into
VLDL1/VLDL2, and the FCR from these density
intervalswasdistinct from that seen forCMapoB48.
ApoB48-containing remnants in TRL especially in
individuals with elevated plasma triglyceride levels
could therefore conceivably arise from the lipolysis
of CM or VLDL1/2, and this has implications for
understanding thenature of theseprime suspects in
atherogenesis [1, 2].
The direct entry of apoB48-containing lipoproteins
into the VLDL density range was a key conceptual
finding in this study that is supported by previ-
ously published data. It is known that chylomi-
crons can differ in size and density, and it has been
proposed that the wide variation in sizes of chy-
lomicrons (35–>250 nm) reflects the supply of
triglycerides to the intestine and affords a mecha-
nism by which TG secretion can be readily altered
in response to diet [49; NB 35 nm would reach
down into the VLDL2 size range]. An electron
microscopic study conducted by Mahley et al.
reported that intestinal Golgi vesicles contain
either CMs or VLDL particles [50, 51], and it has
indeed been proposed that the enterocytes produce
mostly apoB48-VLDL during fasting [52], but fol-
lowing the ingestion of fat, the enterocytes begin to
produce the TG-rich CM particles [50, 53].
This study would not have been possible without
the development of advanced liquid chromatogra-
phy mass spectrometry (LC/MS) analysis. This
methodology has several advantages; the sensitiv-
ity and specificity are superior to earlier technolo-
gies, and it enables information on several protein
kinetics to be obtained at the same [20]. This
minimizes sample volumes required. A weakness
with the technology is that it depends on how well
the protein is converted into peptides. Incomplete
digestion of the protein of interest could contribute
to the discrepancies [20]. Also, the methodology is
technically challenging and expensive and there-
fore not available to all laboratories.
In conclusion, the advanced mass spectrometry
methods and the multicompartment modelling
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presented here have enabled novel insights into the
metabolism of apoB48 in man. Simultaneous
investigation with non-steady-state modelling of
apoB100-containing and apoB48-containing lipo-
proteins in three different density fractions (CM,
VLDL1 and VLDL2), as would occur normally in the
postabsorptive state, has been possible. Our find-
ings reveal novel insights into the metabolism of
apoB48-containing particles in VLDL and the con-
cept that the intestine releases apoB48 at a low
level in fasting conditions but when dietary fat is
present elaborates lipoproteins across a wide size
range. Variation in diet fat quantity and quality is
likely to influence the nature of the particles
generated and with the tools described here, this,
and the consequences for the accumulation of
potentially atherogenic lipoproteins can be exam-
ined with more precision than before.
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